Invokana, Invokamet Get New Warning About Bone Fracture, Low Bone Mineral Density

(September 14, 2015, 11:23 AM EDT) -- SILVER SPRING, Md. — The Food and Drug Administration on Sept. 10 said it added warnings to the label of Invokana and Invokamet diabetes drugs to warn of the increased risk of bone fractures and decreased bone mineral density.

The FDA said the drugs will include a new “warning and precaution” and new “adverse reaction” warning about bone fractures and bone density.

Invokana-brand canagliflozin and Invokana (Invokana with metformin) are made by Janssen Pharmaceuticals Inc. The drugs are part of a class of diabetes drugs known...
To view the full article, register now.